	1	Title:	Association	of	Baseline	Cerebrovascular	Reactivity	and	Longitudinal	Development	t c
--	---	--------	-------------	----	----------	-----------------	------------	-----	--------------	-------------	-----

- 2 Enlarged Perivascular Spaces in the Basal Ganglia
- 3 Short Title: Baseline CVR and longitudinal ePVS development
- 4 Authors: T.J. Libecap<sup>1,2</sup>, Christopher E. Bauer<sup>2</sup>, Valentinos Zachariou<sup>2</sup>, Colleen A. Pappas<sup>2</sup>,
- 5 Flavius D. Raslau<sup>3</sup>, Peiying Liu<sup>4</sup>, Hanzhang Lu<sup>5</sup>, Brian T. Gold<sup>2,3,6,7</sup>
- 6 <sup>1</sup> MD/PhD Program, University of Kentucky College of Medicine, Lexington, Kentucky, USA
- 7 <sup>2</sup> Department of Neuroscience, University of Kentucky College of Medicine, Lexington,
- 8 Kentucky, USA
- <sup>9</sup> <sup>3</sup> Department of Radiology, University of Kentucky College of Medicine, Lexington, Kentucky,
- 10 USA
- <sup>4</sup> Department of Radiology, University of Maryland School of Medicine, Baltimore, Maryland,
- 12 USA
- <sup>5</sup> Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland,
- 14 USA
- <sup>6</sup> Magnetic Resonance Imaging and Spectroscopy Center, University of Kentucky, Lexington,
- 16 Kentucky, USA
- <sup>7</sup> Sanders-Brown Center on Aging University of Kentucky, Lexington, Kentucky, USA

#### 18 **Corresponding Author:**

- 19 Brian T. Gold, PhD
- 20 Brian.Gold@uky.edu
- 21 MN 364 Medical Sciences Building
- 22 780 Rose Street
- 23 Lexington, KY 40536

# 24 Total word count of manuscript: 5982

26	1. Abstract
27	Background: Increasing evidence suggests that enlarged perivascular spaces (ePVS) are
28	associated with cognitive dysfunction in aging. However, the etiology of ePVS remains
29	unknown. Here we tested the possibility that baseline cerebrovascular dysfunction, as measured
30	by an MRI measure of cerebrovascular reactivity (CVR), contributes to the later development of
31	ePVS.
32	Methods: A total of 79 cognitively normal, older adults (46 women, age range 60-84) were
33	recruited to undergo MRI scanning at baseline and 50 participants returned for a follow-up scan
34	approximately 2.5 years later. ePVS were counted in the basal ganglia, centrum semiovale,
35	midbrain, and hippocampus. CVR, an index of the vasodilatory capacity of cerebral small
36	vessels, was assessed using carbon-dioxide inhalation while acquiring blood oxygen-level
37	dependent (BOLD) MR images.
38	Results: Low baseline CVR values in the basal ganglia were associated with increased follow-up
39	ePVS counts in the basal ganglia after controlling for age, sex, and baseline ePVS values
40	(coefficient estimate (SE) = -15.87 (3.92), $p < 0.001$ , 95% confidence interval [CI] -23.68 to -
41	8.05). This effect remained significant after accounting for self-reported risk factors of cerebral
42	small vessel disease (cSVD) (coefficient estimate (SE) = -15.03 (4.00), $p < 0.001$ , CI -23.02 to -
43	7.05) and neuroimaging markers of cSVD (coefficient estimate (SE) = -13.99 (4.02), $p < 0.001$ ,
44	CI -22.03 to -5.95).
45	Conclusions: Our results demonstrate that low baseline CVR is a risk factor for later
46	development of ePVS. MRI-based CVR may represent a promising biomarker of cSVD.
47	
48	

49

5	n
3	υ

### 2. Introduction

Perivascular spaces (PVS) are pial-lined, fluid-filled spaces surrounding penetrating brain arteries <sup>1</sup>. PVS are integral to neuroimmune function and clearance of metabolites via the brain's glymphatic system as the site of interchange between interstitial fluid (ISF) and cerebrospinal fluid (CSF) <sup>2,3</sup>. Enlarged perivascular spaces (ePVS) can be detected as dilated PVS on magnetic resonance imaging (MRI). While originally considered a benign radiological finding, increasing evidence suggests that ePVS may represent microvascular dysfunction and impaired ISF-CSF interchange <sup>1,4</sup>.

58 Consistent with this possibility, a body of work has shown ePVS are associated with 59 cognitive dysfunction in aging <sup>4–8</sup>. For example, we recently found that greater ePVS counts are 60 associated with lower scores on the Montreal Cognitive Assessment (MoCA), a standardized 61 clinical tool of global cognitive performance <sup>8</sup>. In addition, two recent studies showed a 62 relationship between high ePVS burden and worse executive function performance <sup>6,7</sup>.

63 Despite such evidence supporting the clinical significance of ePVS, mechanistic 64 contributors to ePVS remain under-characterized. Functionally-based cerebrovascular dysfunction 65 could represent a contributing factor to structural PVS enlargement. For instance, reduced vascular 66 compliance could disrupt ISF-CSF interchange and impair waste clearance <sup>4,9</sup>. The reduced 67 clearance of brain waste could in turn promote PVS enlargement <sup>3</sup>.

Testing this possibility requires a valid measure of cerebrovascular compliance. Recently, a blood oxygen-level dependent (BOLD)-fMRI cerebrovascular reactivity (CVR) method has been developed and validated as a measure of cerebrovascular compliance <sup>10–12</sup>. This CVR method represents a functional assessment of the ability of the cerebrovascular system to dynamically

respond to a vasodilatory stimulus <sup>11</sup>. Specifically, participants' cerebrovascular response to an inscanner hypercapnia challenge is measured by dividing the percent change in BOLD-fMRI signal
by the change in end-tidal CO<sub>2</sub> (mmHg) between normal room air breathing and hypercapnic air
breathing.

Importantly, several recent studies have described the cross-sectional association between CVR and ePVS  $^{13,14}$ , further motivating a hypothesis that low baseline CVR may contribute to later ePVS. Here, we tested this possibility in a longitudinal design involving a 2.5-year followup sample of older adults who were cognitively normal at baseline. Since the basal ganglia is a known predilection site of early cerebral small vessel disease (cSVD)  $^{15,16}$  that is closely associated with cerebrovascular dysfunction  $^{17-19}$ , we hypothesized that low baseline CVR in the basal ganglia may predict increased ePVS counts in this region.

83

#### 3. Materials and Methods

#### 84 **3.1 Participants**

Eighty-one cognitively normal, older adults (age range 60-84, 46 women) were initially recruited 85 86 for this longitudinal experiment. Participants were recruited from an existing longitudinal cohort 87 at the Sanders-Brown Center on Aging (SBCoA) and the Lexington, KY community. Participants 88 were informed at the time of enrollment that this was a longitudinal study which involved baseline 89 MRI scanning and a follow-up MRI scan approximately 2.5 years later. All participants provided 90 informed written consent at each study time point under a protocol approved by the Institutional 91 Review Board of the University of Kentucky and this study is compliant with STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines <sup>20</sup>. Participants 92 93 were asked not to drink caffeine-based products on the day of their scan to minimize potential 94 confounding effects on CVR. All participants were cognitively unimpaired at baseline based on

either 1) clinical consensus diagnosis and scores from the Uniform Data Set (UDS3) used by US
ADCs (procedure outlined elsewhere <sup>21,22</sup>) or 2) a score of 26 or higher on the Montreal Cognitive
Assessment (MoCA) <sup>23</sup> for those participants recruited from the community.

98 Exclusion criteria at each time point were significant head injury (defined as loss of 99 consciousness for more than 5 min), stroke, neurological disorders (e.g. epilepsy, Alzheimer's 100 disease) or major psychiatric disorders (e.g. schizophrenia, active clinical depression), 101 claustrophobia, pacemakers, the presence of metal fragments or implants that are incompatible 102 with MRI, or significant brain abnormalities detected during imaging. A board-certified 103 neuroradiologist (F.D.R.) evaluated the T1-weighted (T1W) and fluid-attenuated inversion 104 recovery (FLAIR) images for evidence of stroke or other clinically relevant abnormalities. This 105 resulted in exclusion of two participants due to evidence of previous stroke (one participant) and 106 hydrocephalus (one participant), not known at the time of enrollment. Participants were eligible 107 for rescan regardless of their cognitive status at the follow-up scan. Detailed characteristics of the final group of 79 baseline participants and 50 follow-up participants are shown in Table 1. 108

109

#### [Insert Table 1 about here]

### 110 **3.2 Magnetic Resonance Imaging Protocol**

Participants were scanned in a Siemens 3T Prisma scanner (software version E11C), using a 64channel head coil, at the University of Kentucky's Magnetic Resonance Imaging and Spectroscopy Center (MRISC). The following scans were acquired: (1) a 3D multi-echo, T1-weighted magnetization prepared rapid gradient echo (ME-MPRAGE) scan, (2) a 3D fluid-attenuated inversion recovery (FLAIR) scan, (3) a 3D, multi-echo gradient-recalled echo scan used for quantitative susceptibility mapping (QSM), and (4) a BOLD EPI/fMRI scan for assessment of

117	cerebrovascular reactivity (CVR). Several other sequences were collected during the scanning
118	session related to other scientific questions and are not discussed further here.
119	The ME-MPRAGE sequence optimizes gray/white matter contrast <sup>24</sup> and covered the entire
120	brain [1 mm isotropic voxels, $256 \times 256 \times 176$ mm acquisition matrix, parallel imaging (GRAPPA)
121	acceleration = 2, repetition time $(TR) = 2,530$ millisecond (ms), inversion time = 1,100 ms, flip
122	angle (FA) = $7^{\circ}$ , scan duration = 5.88 min] and had four echoes [first echo time (TE1) = 1.69 ms,
123	echo spacing ( $\Delta TE = 1.86 \text{ ms}$ )]. The 3D FLAIR sequence covered the entire brain (1 mm isotropic
124	voxels, $256 \times 256 \times 176$ acquisition matrix, TR = 5,000 ms, TE = 388 ms, inversion time = 1,800
125	ms, scan duration = 6.45 min). A high-resolution, flow compensated, multi-echo, 3D spoiled GRE
126	sequence with eight echoes (TR/TE1/ $\Delta$ TE/FA = 24ms/2.98ms/2.53ms/15°) was acquired and used
127	to create QSM images using Ironsmith, our in-house developed software described elsewhere <sup>25</sup> .
128	The entire brain was covered [1.2 mm isotropic voxels, acquisition matrix = $224 \times 224 \times 144$ ,
129	parallel imaging (GRAPPA) acceleration = 2, and scan duration = 6.18 min]. The CVR sequence
130	covered the entire brain [voxel size of $3.0 \times 3.0 \times 3.7 \text{ mm}^3$ , acquisition matrix = $64 \times 64 \times 36$ ,
131	parallel imaging (GRAPPA) acceleration = 2, $TR = 2,000 \text{ ms}$ , $TE = 30 \text{ ms}$ , $FA = 71^{\circ}$ , number of
132	volumes = 216, and scan duration = $7.20 \text{ min}$ ].

### 133 **3.3 ePVS Counting**

We used a validated, visual rating method for quantification of region-specific ePVS burden developed via collaboration between multiple consortia and intended to standardize ePVS assessment across the field of cSVD research <sup>26</sup>. As described in our previous work <sup>8</sup>, the method involves manually counting ePVS on T1 images, with additional reference to T2 FLAIR images and susceptibility weighted images. Counts were performed in each hemisphere on a single, axial slice of T1 images, within four regions of interest (ROIs) that are known to have the greatest burden

of ePVS <sup>5,15,16,26</sup>: the centrum semiovale, 1 cm above the lateral ventricles; the basal ganglia, at
the level of the columns of the fornix, including the head of the caudate and the putamen (Figure
1); the midbrain, at the level of the cerebral peduncles; the hippocampus, at the level of the
midbrain.

144

#### [Insert Figure 1 about here]

Previous work by multiple consortia such as STandards for ReportIng Vascular changes on nEuroimaging (STRIVE) and Uniform Neuro-Imaging of Virchow-Robin Spaces Enlargement (UNIVRSE) have demonstrated the reliability of counting ePVS on T1, with very high correlation to counts on T2 images <sup>5,27,28</sup> as well as a high correlation between single-slice and multi-slice counts <sup>26,28</sup>. All baseline and follow-up counts were conducted by the lead author (T.J.L.), blinded to participant demographics and neuropsychological scores, and under the supervision of an experienced neuroradiologist (F.D.R.), who clarified unclear imaging features.

In accordance with STRIVE and UNIVRSE consensus guidelines <sup>1,27,28</sup>, ePVS were 152 153 identified using T1, FLAIR and susceptibility weighted images. Prior to counting, each 154 participant's T1 images were registered to their FLAIR and QSM images in native space. ePVS 155 were identified on T1 images as hypointense and less than 3mm in diameter to differentiate them 156 from lacunes, which tend to be larger <sup>27,29</sup>. ePVS were further differentiated from lacunes based 157 on their lack of hyperintensity on FLAIR<sup>27,28</sup>. ePVS were differentiated from cerebral microbleeds 158 (CMBs) by their absence of prominent associated blooming artifact on QSM. We used QSM for 159 differentiation of ePVS and CMBs due to evidence that QSM images outperform traditional single-160 echo susceptibility weighted images in this regard <sup>30</sup>. Intra-rater reliability for ePVS was assessed 161 on a subset of 20 randomly selected participants, using intra-class correlation coefficients (ICC).

### 162 **3.4 Cerebrovascular Reactivity Imaging Procedure**

CVR was assessed using a previously described procedure <sup>10,12,31</sup>. Briefly, participants were fitted 163 164 with a mouthpiece and nose-clip, and mild hypercapnic air (5% carbon dioxide, 74% nitrogen, and 165 21% oxygen) was administered using a Douglas bag, with a two-way non-rebreathing valve, 166 enabling precise switching between room-air and hypercapnic air <sup>31</sup>. Participants underwent 167 blocked inhalation of hypercapnic air and room air while blood oxygen level-dependent (BOLD) 168 MRIs were acquired continuously. A researcher was present inside the scanner room throughout 169 the experiment to manually switch the valve to control the breathing of air (either room air or 170 hypercapnic air from the Douglas bag). An interleaved, blocked fMRI design was used consisting 171 of 3 blocks (50 sec/block) of hypercapnic air, and 4 blocks (70 sec/block) of room air for a total 172 of 430 seconds.  $CO_2$  concentration in the exhaled air was sampled at 100 Hz and the resulting  $CO_2$ 173 trace was recorded using capnography (Philips Respironics NM3 Monitor, Model 7900).

### 174 **3.5 CVR Data Processing**

175 CVR analysis was performed using a cloud-based online processing tool, CVR-MRICloud (Version 5, https://braingps.mricloud.org/cvr.v5)<sup>32,33</sup>. Briefly, the BOLD data were first motion 176 177 corrected and smoothed by an 8mm Gaussian kernel using SPM12. The end-tidal CO<sub>2</sub> (Et-CO<sub>2</sub>) 178 was extracted from the  $CO_2$  trace using an algorithm to identify the peak  $CO_2$  of each exhaled 179 breath. The Et-CO<sub>2</sub> curve was then temporally aligned with the whole-brain averaged BOLD 180 signal time course. Whole-brain CVR values were subsequently obtained using a general linear 181 model (GLM) in which whole-brain averaged BOLD signal was the dependent variable and 182 temporally-aligned Et-CO<sub>2</sub> was the independent variable. The CVR values were scaled to units of 183 %BOLD signal change (in the CO<sub>2</sub>-enhanced vs. normal air condition) per mm of mercury (Hg) 184 of Et-CO<sub>2</sub> change (%BOLD/mmHg CO<sub>2</sub>).

185 Next, the BOLD images for individual participants were co-registered to the T1W ME-186 MPRAGE [(the four echoes averaged into a root mean square (RMS)] image. The T1W images 187 were then segmented into ROIs by the T1 MultiAtlas Segmentation toolbox on MRICloud using 188 the "Adult50-90yrs 287Labels30atlases M2 252 V10A" atlas. These atlas-derived ROI masks 189 were applied to the BOLD images to obtain ROI-averaged BOLD time courses, which were then 190 used in GLM analyses similar to the whole-brain CVR calculation to obtain regional CVR values 191 in specific ROIs (basal ganglia, hippocampus, and midbrain). An ROI mask of the centrum 192 semiovale, which is not included in the CVR-MRICloud toolbox atlas, was also created via an in-193 house developed MATLAB script and FreeSurfer-based masks of the lateral ventricles. 194 Specifically, the centrum semiovale ROI was defined as the portion of a FreeSurfer-derived, 195 whole-brain white matter mask situated between two axial planes, relative to the lateral ventricles. 196 The superior plane of the ROI was 12mm above the superior margin of the lateral ventricles and 197 the inferior plane was 4mm above the superior margin of the lateral ventricles.

Lastly, CVR-MRICloud toolbox also provides the BOLD-CO<sub>2</sub> correlation coefficient as a
 quality control measure. The BOLD-CO<sub>2</sub> correlation coefficient was used to compare the relative
 coupling between BOLD signal and Et-CO<sub>2</sub> between our four ROIs to assess potential differences
 in ROI signal quality.

# 202 **3.6 White Matter Hyperintensity Quantification**

Whole brain white matter hyperintensity (WMH) volumes were computed for use as a control variable in our models testing if CVR predicts change in ePVS after controlling for neuroimaging cSVD variables. Baseline total WMH volumes were computed using the UCD WMH segmentation toolkit (Version 1.3), which employs a validated 4-tissue segmentation method <sup>34</sup>. This pipeline was chosen as it is also used for the Alzheimer's Disease Neuroimaging Initiative (ADNI). Briefly,

208 participants' ME-MPRAGE image [the four echoes averaged into a root mean square (RMS) 209 image] were first registered to their FLAIR image using FLIRT from FMRIB Software Library 210 version 6.0.1<sup>35</sup>. The FLAIR image was then skull stripped, corrected for inhomogeneities using a 211 previously published local histogram normalization <sup>36</sup>, and then non-linearly aligned to a standard 212 atlas <sup>34</sup>. WMHs were estimated in standard space using Bayesian probability based on histogram 213 fitting and prior probability maps. Voxels labeled as WMHs based on these maps exceeded 3.5 214 SDs above the mean WM signal intensity. Manual editing was performed by labeling false positive 215 FLAIR hyperintensity as background. Total WMH volumes were calculated in participants' native 216 FLAIR space after back-transformation and reported in cubic millimeters.

### 217 **3.7 Statistical Analyses**

218 All statistical analyses were performed using SPSS (IBM, Armonk, NY, USA, version 28) with 219 results considered statistically significant at p < 0.05. Independent sample t-tests and paired sample 220 t-tests were used to examine differences between participants who were returners and non-221 returners as well as baseline and follow-up measures, respectively. To test the impact of baseline 222 cerebrovascular dysfunction on longitudinal ePVS burden, a linear mixed effects model (restricted 223 maximum likelihood, identity covariance structure) with random intercepts was performed. 224 Specifically, the predictor variable was baseline CVR value in the basal ganglia and the dependent 225 variable was follow-up basal ganglia ePVS counts after controlling for baseline basal ganglia ePVS 226 counts. Time point was included as a factor in all models and additional covariates were age and 227 sex. Planned models using CVR in other ROIs as a predictor were not run due to relatively low 228 BOLD-CO<sub>2</sub> correlation coefficient (as described in the Results section).

For the ROI showing a significant relationship between baseline CVR and longitudinal ePVS (i.e. the basal ganglia), two follow-up models were run to control for the potential influence of other relevant cSVD factors. In the first follow-up model, available participant-reported cSVD risk factors were added as covariates [body mass index (BMI), hypertension status, and type 2 diabetes status]. BMI was treated as a continuous variable and hypertension status and type 2 diabetes status were treated as dichotomous variables. In a second follow-up model, cSVD neuroimaging measures were added as additional covariates [whole brain WMH volume, lacune counts, and cerebral microbleed counts].

All predictors and dependent variables were tested for the assumption of normality using the Shapiro-Wilk test. Collinearity between predictors in all models was explored using the variance inflation factor (VIF), with a value of 5 implemented as a threshold value <sup>37</sup>. Additionally, continuous covariates were centered.

### 241 **3.8 Data Availability**

The raw data supporting the conclusions of this article will be made available by the authors,without undue reservation.

244

#### 4. Results

#### 245 **4.1 Data Characteristics**

246 High intra-rater reliability was achieved for ePVS counts (ICC = 0.9) on a subset of 20 247 randomly selected participants. The mean follow-up time between the baseline and follow-up scan 248 was 2.56 years (SD = 0.16 years). A summary of mean baseline, follow-up, and change in ePVS 249 values in the 4 ROIs is presented in Table 2. Additionally, an illustrative case of ePVS progression 250 during the follow-up period is presented in Figure 2. Of the 79 participants that underwent baseline 251 MRI scanning, 50 returned for their follow-up MRI. This attrition rate is higher than is typical in 252 our previous longitudinal studies with this cohort and likely reflects, at least in part, concerns 253 related to participation in research during the COVID-19 pandemic. The use of linear mixed effects

254 models, which better handle missing data, allowed us to minimize data loss and maximize power 255 as compared to case-wise deletion methods. Returning participants were not significantly different 256 than non-returners in age at baseline (t = 0.532, p = 0.596), sex (t = -1.093, p = 0.278), or ePVS 257 counts in any of the four counting ROIs (All p > 0.05). However, returners had higher baseline 258 MoCA scores (t = 2.148, p = 0.035) and showed a trend toward having higher mean levels of 259 education (t = 1.971, p = 0.052) than non-returners. During the follow-up period, 7 of the 50 260 returner participants converted from cognitively normal to mild cognitive impairment based on 261 their MoCA scores (range = 22-25).

262

### [Insert Figure 2 about here]

BOLD-CO<sub>2</sub> correlation coefficient, a quality control measure of CVR provided by the CVR-MRICloud toolbox, was significantly higher in the basal ganglia than in the centrum semiovale (t = 73.3, p < 0.001, Supplementary Table 1), midbrain (t = 12.6, p < 0.001, Supplementary Table 1), and hippocampus (t = 10.3, p < 0.001, Supplementary Table 1). For this reason, CVR values in the centrum semiovale, midbrain, and hippocampus were not included in any additional analyses.

CVR values in the basal ganglia (W-statistic = 0.927; p < 0.001) as well as whole brain WMHs (W-statistic = 0.581; p < 0.001) were skewed and therefore log-transformed. Variance inflation factor for all predictors was < 2 and tolerance was > 0.5 in all analyses. Error residuals from all ePVS analyses were normally distributed indicating that the assumption of normality was met.

274

#### [Insert Table 2 about here]

**4.2 Relationship between Baseline CVR Values and Longitudinal ePVS Values** 

276 All results for associations between baseline CVR and ePVS counts are reported in Table 277 3. Baseline log-transformed CVR values in the basal ganglia significantly predicted an increase in 278 basal ganglia ePVS counts over 2.5 years after controlling for baseline ePVS, age, and sex 279 (coefficient estimate (SE) = -15.87 (3.92), p < 0.001, 95% confidence interval [CI] -23.68 to -280 8.05). Baseline CVR values in the basal ganglia did not significantly predict increased ePVS in 281 the centrum semiovale, hippocampus, or midbrain (Supplementary Table 2). To assess possible 282 lateralization effects, the relationships between left and right basal ganglia CVR values and 283 corresponding ePVS values were explored. Results indicated that lower baseline log-transformed 284 CVR values in the left basal ganglia significantly predicted increased ePVS values in the left basal 285 ganglia over time (coefficient estimate (SE) = -7.62 (4.78), p < 0.001, 95% CI -11.85 to -3.38). 286 Similarly, lower baseline log-transformed CVR values in the right basal ganglia significantly 287 predicted increased ePVS values in the right basal ganglia over time (coefficient estimate (SE) = -288 7.91 (2.15), p < 0.001, 95% CI -12.19 to -3.62).

289 Two additional models were conducted to determine the impact of including additional 290 cSVD covariates on the significance of the CVR-ePVS basal ganglia models. Model 2 accounted 291 for participant-reported cSVD risk factors including hypertension status, type 2 diabetes status, 292 and body mass index (BMI). In addition to the cSVD risk factors in Model 2, Model 3 further 293 accounted for several known cSVD neuroimaging markers: lacunes, CMBs, and log-transformed 294 whole brain WMH volume. Results indicated that CVR remained a significant predictor of 295 increased ePVS counts in the basal ganglia over time after controlling for participant-reported 296 cSVD risk factors (Model 2; Table 3) and additional cSVD neuroimaging markers (Model 3; Table 297 3). In addition, when testing potential lateralization effects, the relationships between individual 298 left and right basal ganglia CVR values and corresponding longitudinal basal ganglia ePVS values

remained significant after accounting for both participant-reported cSVD risk factors (Model 2)
and additional cSVD neuroimaging marker covariates (Model 3).
[Insert Table 3 about here]
5. Discussion
We tested whether baseline cerebrovascular reactivity (CVR) contributes to the later development
of enlarged perivascular spaces (ePVS) in community-dwelling older adults. Our results showed
that lower CVR values in the basal ganglia at baseline predicted a longitudinal increase in ePVS
counts in the basal ganglia over a 2.5-year follow-up period. This finding supports a view that
cerebrovascular dysfunction contributes to the development of ePVS in the basal ganglia.
Importantly, the relationship we observed between CVR and ePVS could not be accounted
for by other commonly studied markers of cSVD. Specifically, the relationship between CVR and
ePVS in the basal ganglia remained significant after controlling for the participant-reported cSVD
risk factors of hypertension status, type 2 diabetes status and BMI (Model 2). In addition, the
longitudinal relationship between CVR and ePVS in the basal ganglia remained significant after
controlling for commonly used neuroimaging markers of cSVD including WMH volume, lacune
count, and cerebral microbleed count (Model 3). Together, these results indicate that
cerebrovascular compliance in the basal ganglia, as measured by BOLD-CVR, contributes to the
subsequent development of ePVS in the basal ganglia.
One pathway through which reduced cerebrovascular compliance may lead to increased
ePVS burden relates to glymphatic waste removal. The functional measure of cerebrovascular
reactivity (BOLD-CVR) is an indicator of cerebrovascular compliance and reserve capacity <sup>11,38</sup> .
Diminished cerebrovascular compliance and reduced reserve capacity may impair vasomotion and

pulsatility, which are required for effective glymphatic waste elimination <sup>3,9,39</sup>. Reduced

glymphatic waste removal may in turn lead to accumulation within the PVS and increased ePVS
burden <sup>3</sup>.

While our findings are novel, they are consistent with results from several studies that reported a relationship between non-neuroimaging measures of cerebrovascular dysfunction and PVS enlargement in the basal ganglia. For instance, basal ganglia ePVS are independently related to non-imaging measures of arterial stiffness <sup>17,18</sup>, hypertensive arteriopathy <sup>19,40</sup>, and atherosclerosis <sup>41</sup>. Localization of such findings to the basal ganglia may be in part a result of an increased susceptibility to the early effects of cSVD in the perforating arterioles that supply the basal ganglia <sup>4,42</sup>.

Our results further suggest that rates of ePVS accumulation may differ as a function of brain region. In our sample, a significant longitudinal increase in ePVS burden was observed in 3 brain regions (the basal ganglia, centrum semiovale, and midbrain). In contrast, the hippocampus showed the lowest rate of increase (7.9%), which was not significant in our sample. Future research with larger sample sizes will be needed to establish normative data on ePVS accumulation in different brain regions, the results of which will be of importance to the planning of future clinical trials that use ePVS as an outcome measure.

The main limitation of our study is that BOLD-fMRI is less sensitive in ROIs associated with fewer blood vessels. This resulted in comparably lower BOLD-CO<sub>2</sub> correlation coefficient (quality control) values in the centrum semiovale, midbrain, and hippocampus, which prevented us from performing formal analyses in these ROIs. Furthermore, the relationship between BOLD signal and CO<sub>2</sub> partial pressure may not be linear <sup>43</sup>. As other human biomarker studies, our methods do not allow for conclusions about direct mechanisms. Future research using animal models will be required to delineate the mechanistic pathways through which poor vascular

345 compliance contributes to ePVS development. An additional limitation to our study is our cohort 346 included primarily highly educated, primarily White participants. Our findings will need to be 347 replicated in more ethnically and demographically diverse cohorts.

348 *Conclusions* 

Our results indicate that cerebrovascular dysfunction is a contributing factor to ePVS accumulation in the basal ganglia. Future work should explore additional contributors to ePVS accumulation including the overproduction of proteins associated with neurodegeneration, including  $\beta$ -amyloid and tau. A better understanding of the mechanistic contributors to ePVS accumulation could point to early intervention targets intended to slow or prevent the symptoms associated with cSVD.

355

#### Funding

This work was supported by the National Institutes of Health [grant numbers NIA P30 AG072946 (Brian T. Gold), NIA P30 AG028383 - 15S1 (Brian T. Gold), NIA R01 AG055449 (Brian T. Gold), NIA R01 AG068055 (Brian T. Gold), NINDS RF1 NS122028 (Brian T. Gold), NIBIB P41 EB031771 (Hanzhang Lu), NIA F30 AG079506-01A1 (T.J. Libecap)]. T.J. Libecap was also supported by an award from the American Heart Association (AHA 903649). The content is solely the responsibility of the authors and does not necessarily represent the official views of these granting agencies.

363

#### Acknowledgments

We thank the dedicated research volunteers that make this work possible. We also thank Beverly Meacham, Eric Forman, Beatriz Rodolpho, and Stephen Dundon for assistance with MRI scanning, and Dr. David Powell for assistance with pulse sequence programming and selection. The authors declare no competing financial interests.

368		References
369	1.	Wardlaw JM, Benveniste H, Nedergaard M, et al. Perivascular spaces in the brain:
370		anatomy, physiology and pathology. <i>Nat Rev Neurol</i> . 2020;16(3):137-153.
3/1	2	doi:10.1038/841382-020-0312-Z Iliff II Wang M Liao V et al. A Paravascular Pathway Facilitates CSE Flow Through the
373	2.	Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid $\beta$ . <i>Sci</i>
374	_	<i>Transl Med.</i> 2012;4(147). doi:10.1126/scitranslmed.3003748
375	3.	Kylkilahti TM, Berends E, Ramos M, et al. Achieving brain clearance and preventing
3/6		neurodegenerative diseases—A glymphatic perspective. Journal of Cerebral Blood Flow and Matabolism 2021:41(9):2137-2149. doi:10.1177/0271678X20982388
378	4	Bown CW Carare RO. Schrag MS. Jefferson AL. Physiology and Clinical Relevance of
379		Enlarged Perivascular Spaces in the Aging Brain. <i>Neurology</i> . 2022;98(3):107-117.
380	-	doi:10.1212/WNL.00000000013077
381	5.	Hilal S, Tan CS, Adams HHH, et al. Enlarged perivascular spaces and cognition.
382	6	Passiak BS Liu D Kresge HA et al Perivascular spaces contribute to cognition beyond
384	0.	other small vessel disease markers. <i>Neurology</i> , 2019:92(12):e1309-e1321.
385		doi:10.1212/WNL.000000000007124
386	7.	Choe YM, Baek H, Choi HJ, et al. Association Between Enlarged Perivascular Spaces and
387		Cognition in a Memory Clinic Population. <i>Neurology</i> . 2022;99(13):E1414-E1421.
388		doi:10.1212/WNL.000000000200910
389	8.	Libecap TJ, Zachariou V, Bauer CE, et al. Enlarged Perivascular Spaces Are Negatively
390		Associated With Montreal Cognitive Assessment Scores in Older Adults. <i>Front Neurol.</i>
391	0	2022;13. doi:10.3389/fneur.2022.888511
392	9.	IIIII JJ, Wang M, Zeppenfeld DM, et al. Cerebral arterial pulsation drives paravascular
393 204		CSF-interstitial fluid exchange in the murine brain. <i>Journal of Neuroscience</i> .
394 205	10	Lu H Liu P. Vozhuveth II. Chang V. Marshell O. Go V. MPI menning of corphrovescular
396	10.	reactivity via gas inhalation challenges <i>Journal of Visualized Experiments</i> 2014 (94)
397		doi:10.3791/52306
398	11.	Liu P, de Vis JB, Lu H. Cerebrovascular reactivity (CVR) MRI with CO2 challenge: A
399		technical review. Neuroimage. 2019;187:104-115. doi:10.1016/j.neuroimage.2018.03.047
400	12.	Liu P, Jiang D, Albert M, et al. Multi-vendor and multisite evaluation of cerebrovascular
401		reactivity mapping using hypercapnia challenge. Neuroimage. 2021;245.
402		doi:10.1016/j.neuroimage.2021.118754
403	13.	Blair GW, Thrippleton MJ, Shi Y, et al. Intracranial hemodynamic relationships in
404		patients with cerebral small vessel disease. Neurology. 2020;94(21):e2258-e2269.
405		doi:10.1212/WNL.00000000009483
406	14.	Kapoor A, Yew B, Jang JY, et al. Older adults with perivascular spaces exhibit
407		cerebrovascular reactivity deficits. <i>Neuroimage</i> . Published online November
408	1.5	2022:119/46. doi:10.1016/j.neuroimage.2022.119746
409	15.	Rouni KPW, van Oostenbrugge KJ, Knottnerus ILH, Staals JEA, Lodder J. Virchow-
410 711		KODIN Spaces relate to cerebral small vessel disease severity. J Neurol. 2008;255(5):692-
411		090. doi.10.100//S00413-008-0///-y

412	16.	Doubal FN, MacLullich AMJ, Ferguson KJ, Dennis MS, Wardlaw JM. Enlarged
413		Perivascular Spaces on MRI Are a Feature of Cerebral Small Vessel Disease. Stroke.
414		2010;41(3):450-454. doi:10.1161/STROKEAHA.109.564914
415	17.	Bae JH, Kim JM, Park KY, Han SH. Association between arterial stiffness and the
416		presence of cerebral small vessel disease markers. Brain Behav. 2021;11(1).
417		doi:10.1002/brb3.1935
418	18.	Riba-Llena I, Jiménez-Balado J, Castañé X, et al. Arterial Stiffness Is Associated With
419		Basal Ganglia Enlarged Perivascular Spaces and Cerebral Small Vessel Disease Load.
420		Stroke. 2018;49(5):1279-1281. doi:10.1161/STROKEAHA.118.020163
421	19.	van den Kerkhof M, van der Thiel MM, van Oostenbrugge RJ, et al. Impaired damping of
422		cerebral blood flow velocity pulsatility is associated with the number of perivascular
423		spaces as measured with 7T MRI. Journal of Cerebral Blood Flow & Metabolism.
424		Published online January 26, 2023:0271678X2311533. doi:10.1177/0271678X231153374
425	20.	von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The
426		Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
427		statement: guidelines for reporting observational studies. J Clin Epidemiol.
428		2008;61(4):344-349. doi:10.1016/j.jclinepi.2007.11.008
429	21.	Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): Clinical and
430		Cognitive Variables and Descriptive Data From Alzheimer Disease Centers. Alzheimer
431		Dis Assoc Disord. 2006;20(4):210-216. doi:10.1097/01.wad.0000213865.09806.92
432	22.	Besser L, Kukull W, Knopman DS, et al. Version 3 of the National Alzheimer's
433		Coordinating Center's Uniform Data Set. Alzheimer Dis Assoc Disord. 2018;32(4):351-
434		358. doi:10.1097/WAD.00000000000279
435	23.	Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment,
436		MoCA: A Brief Screening Tool For Mild Cognitive Impairment. J Am Geriatr Soc.
437		2005;53(4):695-699. doi:10.1111/j.1532-5415.2005.53221.x
438	24.	van der Kouwe AJW, Benner T, Salat DH, Fischl B. Brain morphometry with multiecho
439		MPRAGE. Neuroimage. 2008;40(2):559-569. doi:10.1016/j.neuroimage.2007.12.025
440	25.	Zachariou V, Bauer CE, Powell DK, Gold BT. Ironsmith: An automated pipeline for
441		QSM-based data analyses. Neuroimage. 2022;249.
442		doi:10.1016/j.neuroimage.2021.118835
443	26.	Adams HHH, Cavalieri M, Verhaaren BFJ, et al. Rating Method for Dilated Virchow-
444		Robin Spaces on Magnetic Resonance Imaging. Stroke. 2013;44(6):1732-1735.
445		doi:10.1161/STROKEAHA.111.000620
446	27.	Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into
447		small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol.
448		2013;12(8):822-838. doi:10.1016/S1474-4422(13)70124-8
449	28.	Adams HHH, Hilal S, Schwingenschuh P, et al. A priori collaboration in population
450		imaging: The Uniform Neuro-Imaging of Virchow-Robin Spaces Enlargement
451		consortium. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring.
452	• •	2015;1(4):513-520. doi:10.1016/j.dadm.2015.10.004
453	29.	Bokura H, Kobayashi S, Yamaguchi S. Distinguishing silent lacunar infarction from
454		enlarged Virchow-Robin spaces: a magnetic resonance imaging and pathological study. $J$
455		<i>Neurol</i> . 1998;245(2):116-122. doi:10.1007/s004150050189

456	30.	Liu T, Surapaneni K, Lou M, Cheng L, Spincemaille P, Wang Y. Cerebral Microbleeds:
457		Burden Assessment by Using Quantitative Susceptibility Mapping. Radiology.
458		2012;262(1):269-278. doi:10.1148/radiol.11110251
459	31.	Lu H, Kashani AH, Arfanakis K, et al. MarkVCID cerebral small vessel consortium: II.
460		Neuroimaging protocols. Alzheimer's and Dementia. 2021;17(4):716-725.
461		doi:10.1002/alz.12216
462	32.	Mori S, Wu D, Ceritoglu C, et al. MRICloud: Delivering High-Throughput MRI
463		Neuroinformatics as Cloud-Based Software as a Service. <i>Comput Sci Eng.</i> 2016;18(5):21-
464		35. doi:10.1109/MCSE.2016.93
465	33.	Liu P. Baker Z. Li Y. et al. CVR-MRICloud: An online processing tool for CO2-
466		inhalation and resting-state cerebrovascular reactivity (CVR) MRI data. <i>PLoS One</i> .
467		2022:17(9):e0274220. doi:10.1371/iournal.pone.0274220
468	34.	DeCarli C. Maillard P. Fletcher E. Four Tissue Segmentation in ADNI II. Alzheimer's
469	5	Disease Neuroimaging Initiative (2013). Available online at:
470		https://files.alz.washington.edu/documentation/adni_proto.pdf (accessed March 1, 2022)
471	35.	Jenkinson M. Beckmann CF. Behrens TEJ. Woolrich MW. Smith SM. FSL. Neuroimage.
472	55.	2012.62(2):782-790 doi:10.1016/i.neuroimage 2011.09.015
473	36	Decarli C. Murphy DGM. Teichberg D. Campbell G. Sobering GS. Local histogram
474	50.	correction of MRI spatially dependent image pixel intensity nonuniformity. <i>Journal of</i>
475		Magnetic Resonance Imaging 1996.6(3):519-528 doi:10.1002/imri 1880060316
476	37	Stine RA Graphical Interpretation of Variance Inflation Factors Am Stat 1995;49(1):53-
477	57.	56 doi:10.1080/00031305.1995.10476113
478	38	Juttukonda MR Donahue MI Neuroimaging of vascular reserve in patients with
479	50.	cerebrovascular diseases <i>Neuroimage</i> 2019:187:192-208
480		doi:10.1016/i.neuroimage.2017.10.015
481	39.	van Veluw SJ. Hou SS. Calvo-Rodriguez M. et al. Vasomotion as a Driving Force for
482	•••	Paravascular Clearance in the Awake Mouse Brain. <i>Neuron</i> . 2020;105(3):549-561.e5.
483		doi:10.1016/i.neuron.2019.10.033
484	40.	Charidimou A, Boulouis G, Pasi M, et al. MRI-Visible Perivascular Spaces in Cerebral
485		Amyloid Angiopathy and Hypertensive Arteriopathy.; 2017.
486	41.	Du H, Chen C, Ye C, et al. Association Between Steno-Occlusive Middle Cerebral Artery
487		and Basal Ganglia Perivascular Spaces. Front Neurol. 2020;11.
488		doi:10.3389/fneur.2020.00293
489	42.	Rivera-Rivera LA, Schubert T, Turski P, et al. Changes in intracranial venous blood flow
490		and pulsatility in Alzheimer's disease: A 4D flow MRI study. Journal of Cerebral Blood
491		Flow & Metabolism. 2017;37(6):2149-2158. doi:10.1177/0271678X16661340
492	43.	Hou X, Liu P, Li Y, et al. The association between BOLD-based cerebrovascular
493		reactivity (CVR) and end-tidal CO2 in healthy subjects. <i>Neuroimage</i> . 2020;207.
494		doi:10.1016/j.neuroimage.2019.116365
495		
496		
497		
498		
499		
500		
501		

# Table 1

	Baseline	Follow-up
Ν	79	50
Sex (F:M)	46:33	31:19
Age Range (years)	60-84	62-86
Age (years)	69.81 (5.34)	72.6 (5.77)
Education (years)	16.42 (2.48)	16.82 (2.49)
Time Between Scans (years)	-	2.557 (0.158)
MoCA	26.62 (2.55)	26.33 (2.40)
BMI	28.14 (6.17)	27.85 (6.28)
Hypertension, N (%)	34 (43.0)	20 (40.0)
Type 2 Diabetes, N (%)	9 (11.4)	5 (10.0)
Lacunes, N (%)	25 (31.6)	27 (54)
Cerebral microbleeds, N (%)	35 (44.3)	33 (66)

## Demographics and Mean Cognitive Measures

The table lists the mean (±sd) for age, the female to male ratio, years of education, time between baseline and follow-up scan, MoCA scores, and BMI. The number and percentage, N (%), of participants positive for additional self-reported vascular risk factors and cSVD neuroimaging markers are also reported. Baseline MoCA scores were unavailable for 2 participants.

- ,,,,

# Table 2

ePVS ROI	Baseline Count	Follow-up Count	Mean Increase	% Increase	t- statistic	Two-sided p-value
Basal ganglia	(N = 79) 17.90 (4.54)	(N = 50) 21.32 (4.86)	(N = 50) 4.02 (2.73)	23.2	10.415	< 0.001***
Centrum semiovale	52.13 (16.98)	54.34 (15.15)	4.88 (5.40)	9.9	6.394	< 0.001***
Midbrain	3.81 (2.67)	4.72 (2.49)	1.22 (2.10)	34.9	4.103	< 0.001***
Hippocampus	5.70 (2.79)	5.98 (2.58)	0.44 (2.49)	7.9	1.248	0.218

Summary of ePVS values in the 4 ROIs at baseline and follow-up

522 This table lists the mean baseline ( $\pm$ sd), follow-up ( $\pm$ sd) and change ( $\pm$ sd) in ePVS across time

523 points. Paired t-tests show ePVS significantly increased in the basal ganglia, centrum semiovale 524 and midbrain, but not in the hippocampus.

525 \*\*\* $p \le 0.001$ 

## Table 3

ROI Model 1 Model 3 Model 2 -15.87 (3.92), p < -15.03 (4.00), p < -13.99 (4.03), p = Basal 0.001\*\*\*, CI: -22.03 0.001\*\*\*, CI: -23.68 to -0.001\*\*\*, CI: -23.02 to -Ganglia 8.05 7.05 to -5.95 -7.62 (2.13), p < -7.32 (2.16), p < -6.62(2.11), p =Left Basal 0.001\*\*\*, CI: -11.85 to -0.001\*\*\*, CI: -11.62 to -0.003\*\*, CI: -10.84 to Ganglia 3.38 3.01 -2.40 -7.91 (2.15), p < -7.47 (2.20), p = -7.23 (2.22), p = **Right Basal** 0.001\*\*\*, CI: -12.19 to -0.001\*\*\*, CI: -11.86 to -0.002\*\*, CI: -11.66 to Ganglia -2.793.62 3.08

*Mixed effects model: relationship between log-transformed baseline CVR and longitudinal ePVS* 

551 Values are measure coefficient estimate (SE), p value, 95% Confidence Interval. ePVS, enlarged

552 perivascular spaces; BG, basal ganglia.

553 Model 1: adjusted for age, sex, and time point.

554 Model 2: adjusted for covariates in Model 1 and participant-reported hypertension status, type 2 555 diabetes status, and BMI

556 Model 3: adjusted for covariates in Model 2 and lacunes, cerebral microbleeds, and log-557 transformed whole brain WMH

- 558 \*p<0.05
- 559 \*\* $p \le 0.01$
- 560 \*\*\* $p \le 0.001$
- 561
- 562
- 563 564
- 565
- 566
- 567
- 568
- 569 570
- 571
- 572
- 573 574

575

576

577

**Figure 1**: Example of basal ganglia ePVS on a T1-weighted image. An axial slice from representative participant is shown in the plane of the columns of the fornix. ePVS were counted within the head of the caudate (yellow arrow) and putamen (green arrow). A high intra-rater reliability (ICC = 0.9) was achieved for ePVS on a subset of 20 randomly selected participants.



- 598 Figure 2: Example of basal ganglia ePVS burden at baseline and follow-up scan in a representative
- 599 participant. Inset shows high ePVS burden and red arrows indicate several ePVS that developed
- 600 during the follow-up period.
- 601

